House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Hepatology

Metabolic dysfunction-associated steatotic liver disease (MASLD): assessment and management

NICE · 2026 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

This NICE guideline (NG49) covers the assessment and management of metabolic dysfunction-associated steatotic liver disease (MASLD) in children, young people and adults. It addresses: - identifying MASLD in higher-risk groups - ultrasound diagnosis and surveillance in children and young people - testing for advanced liver fibrosis, mainly with the enhanced liver fibrosis (ELF) test, using a 10.51 threshold - referral to hepatology and cirrhosis monitoring - awareness of extra-hepatic risks - lifestyle and alcohol advice - continuing statins - pioglitazone or vitamin E (off label as of July 2016) for advanced fibrosis in specialist settings, with ELF-guided review The guideline defines advanced liver fibrosis as F3 or above (bridging fibrosis) on Kleiner (NASH-CRN) or SAF scoring. Children are aged over 1 year to under 16 years, young people 16 to under 18, and adults 18 or older.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Identifying MASLD

  • MASLD is more common in people with type 2 diabetes or metabolic syndrome, so clinicians should keep it in mind in these groups. [1]
  • Take an alcohol history to exclude alcohol-related liver disease. NICE's cirrhosis guideline is also relevant. [1]
  • Do not rely on routine liver blood tests to exclude MASLD. [1]

Diagnosing MASLD in children and young people

  • Offer liver ultrasound to test for MASLD in children and young people who have type 2 diabetes or metabolic syndrome and who do not misuse alcohol. [1]
  • Refer children with suspected MASLD to a paediatric hepatology specialist in tertiary care. [1]
  • In children and young people, diagnose MASLD when ultrasound shows hepatic steatosis and other suspected causes of steatosis have been excluded. [1]
  • Offer repeat liver ultrasound every 3 years to children and young people who meet all of these criteria: - a normal ultrasound - type 2 diabetes or metabolic syndrome - no alcohol misuse [1]

Assessing advanced liver fibrosis

  • Offer fibrosis testing to people with MASLD: - consider the ELF test once MASLD is diagnosed - do not use routine liver blood tests to assess for advanced fibrosis [1]
  • Diagnose advanced liver fibrosis in people with MASLD who have an ELF score of 10.51 or above. Refer adults and young people with this diagnosis to a hepatology specialist. [1]
  • Tell people with an ELF score below 10.51 that: - advanced fibrosis is unlikely - reassessment every 3 years (adults) or every 2 years (children and young people) is sufficient for regular monitoring - no interim tests are needed Also give advice on changes to physical activity and diet that they may be able to make. [1]
  • Offer fibrosis retesting to people with an ELF score below 10.51 every 3 years for adults and every 2 years for children and young people. [1]
  • ELF may be considered for retesting people who already have advanced liver fibrosis. [1]
  • Monitor adults and young people over 16 with MASLD and advanced fibrosis for cirrhosis, following NICE's cirrhosis guideline. [1]
  • MASLD is a risk factor for type 2 diabetes, hypertension and chronic kidney disease. In people with type 2 diabetes, it is also a risk factor for: - atrial fibrillation - myocardial infarction - ischaemic stroke - cardiovascular death [1]

Healthy living, alcohol and statins

  • Offer physical activity and diet advice to people with MASLD who have overweight or obesity, in line with NICE's overweight and obesity management guideline. [1]
  • Explain that there is some evidence that exercise reduces liver fat. Consider the interventions in the overweight and obesity guideline for people with MASLD whatever their BMI. [1]
  • Do not offer omega-3 fatty acids to adults with MASLD, because the evidence is insufficient. [1]
  • Advise people with MASLD who drink alcohol to stay within national recommended limits. [1]
  • People with MASLD who take statins should continue them. Consider stopping only if liver enzymes double within 3 months of starting a statin, including in people whose baseline liver blood results were abnormal. [1]

Drug treatment for advanced liver fibrosis

  • For adults with advanced fibrosis, with or without diabetes, pioglitazone or vitamin E may be considered, but only in secondary or tertiary care. Before prescribing, weigh comorbidities and their associated adverse-event risks. In July 2016 this use was off label. [1]
  • Use particular caution when prescribing pioglitazone to people at high risk of its adverse effects. It is contraindicated in people with any of: - a history of heart failure - previous or active bladder cancer - uninvestigated macroscopic haematuria Carefully evaluate risk factors for these conditions, including increased age, before treatment, referring to the manufacturers' summaries of product characteristics. [1]
  • Vitamin E may be considered for advanced fibrosis, with or without diabetes: - children: tertiary care only - young people: secondary or tertiary care only In July 2016 this use was off label. [1]
  • Offer retesting 2 years after starting a new drug therapy to judge its effectiveness. The ELF test may be considered for this assessment. [1]
  • If the ELF score rises: - adults: stop vitamin E or pioglitazone and consider switching to the other drug - children and young people: stop vitamin E [1]

Limitations and use

  • Covers only the clinical recommendations and terms. Research recommendations, rationale and update sections were not reviewed.
  • Cirrhosis management (Recs 1.1.2, 1.4.1) and overweight and obesity interventions (Recs 1.6.1, 1.6.3) are cross-referenced to other NICE guidelines and are not detailed here. The national recommended alcohol limits are referenced (Rec 1.6.5) but not specified in this source.
  • The off-label status of pioglitazone and vitamin E is stated as of July 2016. Current licensing was not confirmed from this source.
  • Advanced fibrosis staging is defined histologically (F3 or above on Kleiner/SAF scoring). The guideline uses the ELF threshold of 10.51 for diagnosis.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Metabolic dysfunction-associated steatotic liver disease (MASLD): assessment and management

    Guideline recommendation text consulted

Original guideline

Publication details

Issuing organisation
NICE
First published
6 July 2016
Publisher’s latest update
31 July 2026
Resource type
Clinical guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Identifying MASLD
  • Diagnosing MASLD in children and young people
  • Assessing advanced liver fibrosis
  • Healthy living, alcohol and statins
  • Drug treatment for advanced liver fibrosis
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House